Decreased PGE2 content reduces MMP-1 activity and consequently increases collagen density in human varicose vein

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Gomez, Ingrid ^a,b   Benyahia, Chabha ^a,b   Louedec, Liliane ^a   Leséche, Guy ^a,c   Jacob, Marie Paule ^a   Longrois, Dan ^a,c   Norel, Xavier ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; COLLAGEN; CYTOSOLIC PROSTAGLANDIN E SYNTHASE; GELATINASE A; INTERSTITIAL COLLAGENASE; MESSENGER RNA; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E RECEPTOR 4 ANTAGONIST; PROSTAGLANDIN E SYNTHASE; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E SYNTHASE 2; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD VESSEL PARAMETERS; CLINICAL ARTICLE; COLLAGEN DENSITY; COLLAGEN METABOLISM; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PATHOPHYSIOLOGY; PROSTAGLANDIN DEGRADATION; PROSTAGLANDIN METABOLISM; PROTEIN CONTENT; PROTEIN EXPRESSION; SAPHENOUS VEIN; VARICOSIS; VASCULAR DISEASE; VASCULAR WALL REMODELING; VASCULAR WALL THICKENING; VEIN DIAMETER; VEIN STRIPPING; VENOUS STASIS;

AGED; COLLAGEN; DINOPROSTONE; FEMALE; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; INTRAMOLECULAR OXIDOREDUCTASES; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; RNA, MESSENGER; SAPHENOUS VEIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; VARICOSE VEINS;

EID: 84895524336     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088021     Document Type: Article

References (59)

1. Raffetto JD, Khalil RA (2008) Mechanisms of varicose vein formation: valve dysfunction and wall dilation. Phlebology 23: 85-98.
2. Lim CS, Davies AH (2009) Pathogenesis of primary varicose veins. Br J Surg 96: 1231-1242.
3. Golledge J, Quigley FG (2003) Pathogenesis of varicose veins. Eur J Vasc Endovasc Surg 25: 319-324. (Pubitemid 36527629)
4. Oklu R, Habito R, Mayr M, Deipolyi AR, Albadawi H, et al. (2012) Pathogenesis of varicose veins. J Vasc Interv Radiol 23: 33-39.
5. Bergan JJ, Schmid-Schonbein GW, Smith PD, Nicolaides AN, Boisseau MR, et al. (2006) Chronic venous disease. N Engl J Med 355: 488-498. (Pubitemid 44162276)
6. Foudi N, Gomez I, Benyahia C, Longrois D, Norel X (2012) Prostaglandin E(2) receptor subtypes in human blood and vascular cells. Eur J Pharmacol 695: 1-6.
7. Norel X (2007) Prostanoid receptors in the human vascular wall. ScientificWorldJournal 7: 1359-1374.
8. Foudi N, Louedec L, Cachina T, Brink C, Norel X (2009) Selective cyclooxygenase-2 inhibition directly increases human vascular reactivity to norepinephrine during acute inflammation. Cardiovasc Res 81: 269-277.
9. Gomez I, Foudi N, Longrois D, Norel X (2013) The role of prostaglandin E in human vascular inflammation. Prostaglandins Leukot Essent Fatty Acids.
10. Gomez PF, Pillinger MH, Attur M, Marjanovic N, Dave M, et al. (2005) Resolution of inflammation: prostaglandin E2 dissociates nuclear trafficking of individual NF-kappaB subunits (p65, p50) in stimulated rheumatoid synovial fibroblasts. J Immunol 175: 6924-6930. (Pubitemid 41598938)
11. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B (1999) Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A 96: 7220-7225. (Pubitemid 29299642)
12. Camacho M, Gerboles E, Escudero JR, Anton R, Garcia-Moll X, et al. (2007) Microsomal prostaglandin E synthase-1, which is not coupled to a particular cyclooxygenase isoenzyme, is essential for prostaglandin E(2) biosynthesis in vascular smooth muscle cells. J Thromb Haemost 5: 1411-1419. (Pubitemid 46969879)
13. St-Jacques B, Ma W (2013) Prostaglandin E2/EP4 signalling facilitates EP4 receptor externalization in primary sensory neurons in vitro and in vivo. Pain 154: 313-323.
14. Lee J, Banu SK, Subbarao T, Starzinski-Powitz A, Arosh JA (2011) Selective inhibition of prostaglandin E2 receptors EP2 and EP4 inhibits invasion of human immortalized endometriotic epithelial and stromal cells through suppression of metalloproteinases. Mol Cell Endocrinol 332: 306-313.
15. Park JY, Pillinger MH, Abramson SB (2006) Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin Immunol 119: 229-240. (Pubitemid 44269070)
16. Gudis K, Tatsuguchi A, Wada K, Futagami S, Nagata K, et al. (2005) Microsomal prostaglandin E synthase (mPGES)-1, mPGES-2 and cytosolic PGES expression in human gastritis and gastric ulcer tissue. Lab Invest 85: 225-236. (Pubitemid 40208926)
17. Thoren S, Weinander R, Saha S, Jegerschold C, Pettersson PL, et al. (2003) Human microsomal prostaglandin E synthase-1: purification, functional characterization, and projection structure determination. J Biol Chem 278: 22199-22209. (Pubitemid 36830265)
18. Samuelsson B, Morgenstern R, Jakobsson PJ (2007) Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 59: 207-224. (Pubitemid 47481434)
19. Gomez I, Benyahia C, Le Dall J, Payre C, Louedec L, et al. (2013) Absence of inflammatory conditions in human varicose saphenous veins. Inflamm Res 62: 299-308.
20. Yen JH, Kocieda VP, Jing H, Ganea D (2011) Prostaglandin E2 induces matrix metalloproteinase 9 expression in dendritic cells through two independent signaling pathways leading to activator protein 1 (AP-1) activation. J Biol Chem 286: 38913-38923.
21. Sanchez C, Gabay O, Salvat C, Henrotin YE, Berenbaum F (2009) Mechanical loading highly increases IL-6 production and decreases OPG expression by osteoblasts. Osteoarthritis Cartilage 17: 473-481.
22. Yokoyama U, Ishiwata R, Jin MH, Kato Y, Suzuki O, et al. (2012) Inhibition of EP4 signaling attenuates aortic aneurysm formation. PLoS One 7: e36724.
23. Vargova V, Pytliak M, Mechirova V (2012) Matrix metalloproteinases. Exs 103: 1-33.
24. Benjamin MM, Khalil RA (2012) Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. Exs 103: 209-279.
25. Jacob MP (2003) Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. Biomed Pharmacother 57: 195-202.
26. Gomez-Hernandez A, Sanchez-Galan E, Ortego M, Martin-Ventura JL, Blanco-Colio LM, et al. (2008) Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome. Am J Cardiol 102: 12-18.
27. Cipollone F, Fazia M, Iezzi A, Ciabattoni G, Pini B, et al. (2004) Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans. Arterioscler Thromb Vasc Biol 24: 1259-1265. (Pubitemid 38880018)
28. Newby AC (2012) Matrix metalloproteinase inhibition therapy for vascular diseases. Vascul Pharmacol 56: 232-244.
29. Kurihara T, Shimizu-Hirota R, Shimoda M, Adachi T, Shimizu H, et al. (2012) Neutrophil-derived matrix metalloproteinase 9 triggers acute aortic dissection. Circulation 126: 3070-3080.
30. Sansilvestri-Morel P, Fioretti F, Rupin A, Senni K, Fabiani JN, et al. (2007) Comparison of extracellular matrix in skin and saphenous veins from patients with varicose veins: does the skin reflect venous matrix changes? Clin Sci (Lond) 112: 229-239.
31. Kowalewski R, Sobolewski K, Wolanska M, Gacko M (2004) Matrix metalloproteinases in the vein wall. Int Angiol 23: 164-169. (Pubitemid 39419779)
32. Gillespie DL, Patel A, Fileta B, Chang A, Barnes S, et al. (2002) Varicose veins possess greater quantities of MMP-1 than normal veins and demonstrate regional variation in MMP-1 and MMP-13. J Surg Res 106: 233-238.
33. Badier-Commander C, Verbeuren T, Lebard C, Michel JB, Jacob MP (2000) Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation. J Pathol 192: 105-112.
34. Kucukguven A, Khalil RA (2013) Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins. Curr Drug Targets 14: 287-324.
35. Wilson RJ, Giblin GM, Roomans S, Rhodes SA, Cartwright KA, et al. (2006) GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl) phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. Br J Pharmacol 148: 326-339. (Pubitemid 43801180)
36. Ho-Tin-Noe B, Le Dall J, Gomez D, Louedec L, Vranckx R, et al. (2011) Early atheroma-derived agonists of peroxisome proliferator-activated receptor-gamma trigger intramedial angiogenesis in a smooth muscle cell-dependent manner. Circ Res 109: 1003-1014.
37. Badier-Commander C, Couvelard A, Henin D, Verbeuren T, Michel JB, et al. (2001) Smooth muscle cell modulation and cytokine overproduction in varicose veins. An in situ study. J Pathol 193: 398-407. (Pubitemid 32229874)
38. Chen L, Yang G, Xu X, Grant G, Lawson JA, et al. (2013) Cell selective cardiovascular biology of microsomal prostaglandin E synthase-1. Circulation 127: 233-243.
39. Murakami M, Nakashima K, Kamei D, Masuda S, Ishikawa Y, et al. (2003) Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J Biol Chem 278: 37937-37947. (Pubitemid 37175324)
40. Bage T, Kats A, Lopez BS, Morgan G, Nilsson G, et al. (2011) Expression of prostaglandin E synthases in periodontitis immunolocalization and cellular regulation. Am J Pathol 178: 1676-1688.
41. Payner T, Leaver HA, Knapp B, Whittle IR, Trifan OC, et al. (2006) Microsomal prostaglandin E synthase-1 regulates human glioma cell growth via prostaglandin E(2)-dependent activation of type II protein kinase A. Mol Cancer Ther 5: 1817-1826. (Pubitemid 44323250)
42. Mendez M, LaPointe MC (2003) PPARgamma inhibition of cyclooxygenase-2, PGE2 synthase, and inducible nitric oxide synthase in cardiac myocytes. Hypertension 42: 844-850. (Pubitemid 37237334)
43. Foudi N, Kotelevets L, Gomez I, Louedec L, Longrois D, et al. (2011) Differential reactivity of human mammary artery and saphenous vein to prostaglandin E(2) : implication for cardiovascular grafts. Br J Pharmacol 163: 826-834.
44. Bishop-Bailey D, Pepper JR, Haddad EB, Newton R, Larkin SW, et al. (1997) Induction of cyclooxygenase-2 in human saphenous vein and internal mammary artery. Arterioscler Thromb Vasc Biol 17: 1644-1648. (Pubitemid 27423981)
45. Pham H, Chen M, Li A, King J, Angst E, et al. (2010) Loss of 15-hydroxyprostaglandin dehydrogenase increases prostaglandin E2 in pancreatic tumors. Pancreas 39: 332-339.
46. Parra JR, Cambria RA, Hower CD, Dassow MS, Freischlag JA, et al. (1998) Tissue inhibitor of metalloproteinase-1 is increased in the saphenofemoral junction of patients with varices in the leg. J Vasc Surg 28: 669-675. (Pubitemid 28481222)
47. Woodside KJ, Hu M, Burke A, Murakami M, Pounds LL, et al. (2003) Morphologic characteristics of varicose veins: possible role of metalloproteinases. J Vasc Surg 38: 162-169. (Pubitemid 41123304)
48. Aravind B, Saunders B, Navin T, Sandison A, Monaco C, et al. (2010) Inhibitory effect of TIMP influences the morphology of varicose veins. Eur J Vasc Endovasc Surg 40: 754-765.
49. Chang JW, Maeng YH, Kim SW (2011) Expression of matrix metalloproteinase-2 and -13 and tissue inhibitor of metalloproteinase-4 in varicose veins. Korean J Thorac Cardiovasc Surg 44: 387-391.
50. Ishikawa Y, Asuwa N, Ishii T, Ito K, Akasaka Y, et al. (2000) Collagen alteration in vascular remodeling by hemodynamic factors. Virchows Arch 437: 138-148. (Pubitemid 30623573)
51. Kar S, Subbaram S, Carrico PM, Melendez JA (2010) Redox-control of matrix metalloproteinase-1: a critical link between free radicals, matrix remodeling and degenerative disease. Respir Physiol Neurobiol 174: 299-306.
52. Gandhi RH, Irizarry E, Nackman GB, Halpern VJ, Mulcare RJ, et al. (1993) Analysis of the connective tissue matrix and proteolytic activity of primary varicose veins. J Vasc Surg 18: 814-820. (Pubitemid 23346905)
53. Sansilvestri-Morel P, Rupin A, Badier-Commander C, Kern P, Fabiani JN, et al. (2001) Imbalance in the synthesis of collagen type I and collagen type III in smooth muscle cells derived from human varicose veins. J Vasc Res 38: 560-568. (Pubitemid 33151596)
54. Cipollone F, Fazia ML, Iezzi A, Cuccurullo C, De Cesare D, et al. (2005) Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. Arterioscler Thromb Vasc Biol 25: 1925-1931. (Pubitemid 41243464)
55. Takayama K, Garcia-Cardena G, Sukhova GK, Comander J, Gimbrone MA, Jr., et al. (2002) Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 277: 44147-44154. (Pubitemid 36157844)
56. Hasan D, Hashimoto T, Kung D, Macdonald RL, Winn HR, et al. (2012) Upregulation of cyclooxygenase-2 (COX-2) and microsomal prostaglandin E2 synthase-1 (mPGES-1) in wall of ruptured human cerebral aneurysms: preliminary results. Stroke 43: 1964-1967.
57. Reilly JM, Miralles M, Wester WN, Sicard GA (1999) Differential expression of prostaglandin E2 and interleukin-6 in occlusive and aneurysmal aortic disease. Surgery 126: 624-627; discussion 627-628.
58. Cao RY, St Amand T, Li X, Yoon SH, Wang CP, et al. (2012) Prostaglandin receptor EP4 in abdominal aortic aneurysms. Am J Pathol 181: 313-321.
59. Wang M, Lee E, Song W, Ricciotti E, Rader DJ, et al. (2008) Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation 117: 1302-1309. (Pubitemid 351365673)